Role of dopamine agonists in Parkinson's disease therapy.
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
13
03
2023
accepted:
27
04
2023
medline:
22
5
2023
pubmed:
11
5
2023
entrez:
10
5
2023
Statut:
ppublish
Résumé
Dopamine agonists are an important component of Parkinson's therapy. When weighing up the various therapy options, therapy with levodopa has recently been increasingly preferred due to its stronger efficacy and the ostensibly lower rate of side effects. The advantage of the lower incidence of motor complications during therapy with dopamine agonists was neglected. The occurrence of side effects can be explained by the different receptor affinity to the individual dopaminergic and non-dopaminergic receptors of the individual dopamine agonists. However, the different affinity to individual receptors also explains the different effect on individual Parkinson symptoms and can, therefore, contribute to a targeted use of the different dopamine agonists. Since comparative studies on the differential effect of dopamine agonists have only been conducted for individual substances, empirical knowledge of the differential effect is of great importance. Therefore, the guidelines for the treatment of Parkinson's disease do not consider the differential effect of the dopamine agonists. The historical consideration of dopamine agonists within Parkinson's therapy deserves special attention to be able to classify the current discussion about the significance of dopamine agonists.
Identifiants
pubmed: 37165120
doi: 10.1007/s00702-023-02647-0
pii: 10.1007/s00702-023-02647-0
doi:
Substances chimiques
Dopamine Agonists
0
Antiparkinson Agents
0
Levodopa
46627O600J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
863-873Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Agid Y (2001) Levodopa. Is toxicity a myth? 1998. Neurology 57:S46–S51
pubmed: 11775601
Alexander SPH, Christopoulos A, Davenport AP et al (2021) The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br J Pharmacol 178:S27–S156. https://doi.org/10.1111/BPH.15538/FULL
doi: 10.1111/BPH.15538/FULL
pubmed: 34529832
Antonelli T, Fuxe K, Agnati L et al (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson’s disease. Relevance for L-dopa induced dyskinesias. J Neurol Sci 248:16–22. https://doi.org/10.1016/j.jns.2006.05.019
doi: 10.1016/j.jns.2006.05.019
pubmed: 16765381
Baik JH, Picetti R, Saiardi A et al (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377:424–428. https://doi.org/10.1038/377424A0
doi: 10.1038/377424A0
pubmed: 7566118
Barbeau A (1962) Parkinson’s disease. Union Med Can 91:539–540
pubmed: 13864825
Barcroft H, Schwab RS (1951) The effect of apomorphine and that of adrenalin, on the tremor of Parkinson’s disease. J Nerv Ment Dis 114:541–542
pubmed: 14898289
Bartl M, Dakna M, Schade S et al (2022) Longitudinal change and progression indicators using the movement disorder society-unified Parkinson’s disease rating scale in two independent cohorts with early Parkinson’s disease. J Parkinsons Dis 12:437–452. https://doi.org/10.3233/JPD-212860
doi: 10.3233/JPD-212860
pubmed: 34719511
Beaulieu M (1987) Clinical importance of D-1 and D-2 receptors. Can J Neurol Sci 14:402–406. https://doi.org/10.1017/s031716710003780x
doi: 10.1017/s031716710003780x
pubmed: 2960428
Béreau M, Krack P, Brüggemann N, Münte TF (2019) Neurobiology and clinical features of impulse control failure in Parkinson’s disease. Neurol Res Pract. https://doi.org/10.1186/S42466-019-0013-5
doi: 10.1186/S42466-019-0013-5
pubmed: 33324875
pmcid: 7650064
Binde CD, Tvete IF, Gåsemyr JI et al (2020) Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol 76:1731–1743. https://doi.org/10.1007/S00228-020-02961-6
doi: 10.1007/S00228-020-02961-6
pubmed: 32710141
pmcid: 7661406
Birkmayer W, Hornykiewicz O (1961) The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787–788
pubmed: 13869404
Bouthenet ML, Souil E, Martres MP et al (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564:203–219. https://doi.org/10.1016/0006-8993(91)91456-B
doi: 10.1016/0006-8993(91)91456-B
pubmed: 1839781
Bunzow JR, van Tol HHM, Grandy DK et al (1988a) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336:783–787. https://doi.org/10.1038/336783a0
doi: 10.1038/336783a0
pubmed: 2974511
Calne DB, Reid JL, Vakil SD et al (1971) Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J 3:729. https://doi.org/10.1136/BMJ.3.5777.729
doi: 10.1136/BMJ.3.5777.729
pubmed: 4938431
pmcid: 1798919
Calne DB, Teychenne PF, Claveria LE et al (1974) Bromocriptine in parkinsonism. Br Med J 4:442–444. https://doi.org/10.1136/bmj.4.5942.442
doi: 10.1136/bmj.4.5942.442
pubmed: 4425916
pmcid: 1612580
Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200–1200. https://doi.org/10.1038/1801200a0
doi: 10.1038/1801200a0
pubmed: 13483658
Cheshire P, Bertram K, Ling H et al (2014) Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson’s disease. Neurodegener Dis 13:24–28. https://doi.org/10.1159/000351097
doi: 10.1159/000351097
pubmed: 24008922
Chien EYT, Liu W, Zhao Q et al (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (1979) 330:1091–1095. https://doi.org/10.1126/science.1197410
doi: 10.1126/science.1197410
Clarke CE, Speller J, Clarke JA (2000) Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002259/MEDIA/CDSR/CD002259/IMAGE_N/NCD002259-CMP-001-14.PNG
doi: 10.1002/14651858.CD002259/MEDIA/CDSR/CD002259/IMAGE_N/NCD002259-CMP-001-14.PNG
pubmed: 10908504
pmcid: 8407493
Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med 280:337–345. https://doi.org/10.1056/NEJM196902132800701
doi: 10.1056/NEJM196902132800701
pubmed: 4178641
de Lau LML, Verbaan D, Marinus J et al (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord 27:132–135. https://doi.org/10.1002/MDS.23805
doi: 10.1002/MDS.23805
pubmed: 22083803
de Tosin MHS, Goetz CG, Luo S et al (2020) Item response theory analysis of the MDS-UPDRS motor examination: tremor vs. nontremor items. Mov Disord 35:1587–1595. https://doi.org/10.1002/mds.28110
doi: 10.1002/mds.28110
pubmed: 32469456
Deutch AY (2006) Striatal plasticity in Parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease. J Neural Transm. https://doi.org/10.1007/978-3-211-45295-0_12
doi: 10.1007/978-3-211-45295-0_12
Eckart C, Bunzeck N (2013) Dopamine modulates processing speed in the human mesolimbic system. Neuroimage 66:293–300. https://doi.org/10.1016/j.neuroimage.2012.11.001
doi: 10.1016/j.neuroimage.2012.11.001
pubmed: 23142277
Ehringer H, Hornykiewicz O (1960) Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems. Klin Wochenschr 38:1236–1239. https://doi.org/10.1007/BF01485901/METRICS
doi: 10.1007/BF01485901/METRICS
pubmed: 13726012
Fahn S (1974) “On-off” phenomenon with levodopa therapy in parkinsonism. Neurology 24:431–431. https://doi.org/10.1212/WNL.24.5.431
doi: 10.1212/WNL.24.5.431
pubmed: 4857104
Foltynie T, Cheeran B, Williams-Gray CH et al (2009) BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80:141–144. https://doi.org/10.1136/JNNP.2008.154294
doi: 10.1136/JNNP.2008.154294
pubmed: 18977816
Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Targets 19:377–398. https://doi.org/10.1517/14728222.2014.981529
doi: 10.1517/14728222.2014.981529
pubmed: 25486101
Gerlach M, Double K, Arzberger T et al (2003) Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110:1119–1127. https://doi.org/10.1007/s00702-003-0027-5
doi: 10.1007/s00702-003-0027-5
pubmed: 14523624
Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptor activation. Neurology 33:1489–1492. https://doi.org/10.1212/wnl.33.11.1489
doi: 10.1212/wnl.33.11.1489
pubmed: 6605497
Goetz CG (1998) Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology. https://doi.org/10.1212/wnl.50.5_suppl_5.s26
doi: 10.1212/wnl.50.5_suppl_5.s26
pubmed: 9748031
Gottwald MD, Bainbridge JL, Dowling GA et al (1997) New pharmacotherapy for Parkinson’s disease. Ann Pharmacother 31:1205–1217. https://doi.org/10.1177/106002809703101014
doi: 10.1177/106002809703101014
pubmed: 9337447
Gray R, Ives N, Rick C et al (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196–1205. https://doi.org/10.1016/S0140-6736(14)60683-8
doi: 10.1016/S0140-6736(14)60683-8
pubmed: 24928805
Grosset KA, Grosset DG (2005) Patient-perceived involvement and satisfaction in Parkinson’s disease: effect on therapy decisions and quality of life. Mov Disord 20:616–619. https://doi.org/10.1002/mds.20393
doi: 10.1002/mds.20393
pubmed: 15719417
Grosset KA, Bone I, Grosset DG (2005) Suboptimal medication adherence in Parkinson’s disease. Mov Disord 20:1502–1507. https://doi.org/10.1002/mds.20602
doi: 10.1002/mds.20602
pubmed: 16037924
Guigoni C, Aubert I, Li Q et al (2005) Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2004.11.005
doi: 10.1016/j.parkreldis.2004.11.005
pubmed: 15885624
Hildick-Smith M (1976) Letter: alternatives to levodopa. Br Med J 1:1406. https://doi.org/10.1136/bmj.1.6022.1406
doi: 10.1136/bmj.1.6022.1406
pubmed: 1276722
pmcid: 1640072
Hilger D, Masureel M, Kobilka BK (2018) Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol 25:4–12. https://doi.org/10.1038/S41594-017-0011-7
doi: 10.1038/S41594-017-0011-7
pubmed: 29323277
pmcid: 6535338
Huang X, Lawler CP, Lewis MM et al (2001) D1 dopamine receptors. Int Rev Neurobiol 48:65–139. https://doi.org/10.1016/s0074-7742(01)48014-7
doi: 10.1016/s0074-7742(01)48014-7
pubmed: 11526741
Huang X, Lewis MM, Jodi Van Scoy L et al (2020) The D 1 /D 5 dopamine partial agonist PF-06412562 in advanced stage Parkinson’s disease: a feasibility study HHS public access. J Parkinsons Dis 10:1515–1527. https://doi.org/10.3233/JPD-202188
doi: 10.3233/JPD-202188
pubmed: 32986682
pmcid: 8640973
Iravani MM, Haddon CO, Cooper JM et al (2006) Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96:1315–1321. https://doi.org/10.1111/j.1471-4159.2005.03625.x
doi: 10.1111/j.1471-4159.2005.03625.x
pubmed: 16464239
Jenner P, Taylor AR, Campbell DB (1973) Letter: preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent. J Pharm Pharmacol 25:749–750. https://doi.org/10.1111/J.2042-7158.1973.TB10060.X
doi: 10.1111/J.2042-7158.1973.TB10060.X
pubmed: 4148514
Jones-Tabah J, Mohammad H, Paulus EG et al (2022) The signaling and pharmacology of the dopamine D1 receptor. Front Cell Neurosci. https://doi.org/10.3389/FNCEL.2021.806618
doi: 10.3389/FNCEL.2021.806618
pubmed: 35110997
pmcid: 8801442
Jost WH, Buhmann C, Classen J et al (2022) Relevance of COMT inhibitors in the treatment of motor fluctuations. Nervenarzt 93:1035–1045. https://doi.org/10.1007/S00115-021-01237-3
doi: 10.1007/S00115-021-01237-3
pubmed: 35044481
Kaplan N, Vituri A, Korczyn AD et al (2014) Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease. J Mol Neurosci 53:183–188. https://doi.org/10.1007/S12031-014-0276-9
doi: 10.1007/S12031-014-0276-9
pubmed: 24633632
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96. https://doi.org/10.1038/277093a0
doi: 10.1038/277093a0
pubmed: 215920
Klicken oder tippen Sie hier, um Text einzugeben.
Kurlan R, Rothfield KP, Woodward WR et al (1988) Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 38:419–421. https://doi.org/10.1212/wnl.38.3.419
doi: 10.1212/wnl.38.3.419
pubmed: 3126408
Kurth MC, Adler CH (1998) COMT inhibition: a new treatment strategy for Parkinson’s disease. Neurology. https://doi.org/10.1212/wnl.50.5_suppl_5.s3
doi: 10.1212/wnl.50.5_suppl_5.s3
pubmed: 9591521
Li BD, Cui JJ, Song J et al (2018) Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson’s disease: a network meta-analysis. Cell Physiol Biochem 45:119–130. https://doi.org/10.1159/000486252
doi: 10.1159/000486252
pubmed: 29339630
Lieberman AN, Leibowitz M, Neophytides A et al (1979) Pergolide and lisuride for Parkinson’s disease. Lancet 2:1129–1130. https://doi.org/10.1016/S0140-6736(79)92524-8
doi: 10.1016/S0140-6736(79)92524-8
pubmed: 91856
Luo S, Zou H, Stebbins GT et al (2022) Dissecting the domains of Parkinson’s disease: insights from longitudinal item response theory modeling. Mov Disord 37:1904–1914. https://doi.org/10.1002/MDS.29154
doi: 10.1002/MDS.29154
pubmed: 35841312
pmcid: 9897939
Mailman RB, Nichols DE, Williams M (1998) Dopamine D1 receptor agonists as antiparkinson drugs [3] (multiple letters). Trends Pharmacol Sci 19:255–256. https://doi.org/10.1016/S0165-6147(98)01219-X
doi: 10.1016/S0165-6147(98)01219-X
pubmed: 9703756
Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson`s disease. Lancet 309:345–349. https://doi.org/10.1016/S0140-6736(77)91146-1
doi: 10.1016/S0140-6736(77)91146-1
Martini ML, Ray C, Yu X et al (2019) Designing functionally selective noncatechol dopamine D1 receptor agonists with potent in vivo antiparkinsonian activity. ACS Chem Neurosci 10:4160–4182. https://doi.org/10.1021/ACSCHEMNEURO.9B00410
doi: 10.1021/ACSCHEMNEURO.9B00410
pubmed: 31387346
Masellis M, Collinson S, Freeman N et al (2016) Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 139:2050–2062. https://doi.org/10.1093/BRAIN/AWW109
doi: 10.1093/BRAIN/AWW109
pubmed: 27190009
Millan MJ (2010a) From the cell to the clinic: a comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther 128:229–273. https://doi.org/10.1016/j.pharmthera.2010.06.002
doi: 10.1016/j.pharmthera.2010.06.002
pubmed: 20600305
Millan MJ, Maiofiss L, Cussac D et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804. https://doi.org/10.1124/jpet.102.039867
doi: 10.1124/jpet.102.039867
pubmed: 12388666
Muhlack S, Herrmann L, Salmen S, Müller T (2014) Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm 121:1357–1366. https://doi.org/10.1007/s00702-014-1213-3
doi: 10.1007/s00702-014-1213-3
pubmed: 24770794
Newman-Tancredi A, Cussac D, Audinot V et al (2002a) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor. J Pharmacol Exp Ther 303:805–814. https://doi.org/10.1124/jpet.102.039875
doi: 10.1124/jpet.102.039875
pubmed: 12388667
Newman-Tancredi A, Cussac D, Quentric Y et al (2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes. J Pharmacol Exp Ther 303:815–822. https://doi.org/10.1124/jpet.102.039883
doi: 10.1124/jpet.102.039883
pubmed: 12388668
Nyholm D, Lennernäs H (2008) Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol 4:193–203. https://doi.org/10.1517/17425255.4.2.193
doi: 10.1517/17425255.4.2.193
pubmed: 18248312
Oliveri RL, Annesi G, Zappia M et al (1999) Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 53:1425–1430. https://doi.org/10.1212/wnl.53.7.1425
doi: 10.1212/wnl.53.7.1425
pubmed: 10534246
Ong WY, Leow DMK, Herr DR, Yeo CJJ (2022) What do randomized controlled trials inform us about potential disease-modifying strategies for Parkinson’s disease? Neuromolecular Med. https://doi.org/10.1007/S12017-022-08718-X
doi: 10.1007/S12017-022-08718-X
pubmed: 36261765
pmcid: 9023728
Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563–570. https://doi.org/10.1001/ARCHNEUR.66.1.NCT90001
doi: 10.1001/ARCHNEUR.66.1.NCT90001
Parkinson’s Disease Research Group in the United Kingdom (1993) Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three year interim report. BMJ 307:469–472. https://doi.org/10.1136/BMJ.307.6902.469
doi: 10.1136/BMJ.307.6902.469
Quinn N, Critchley P, Parkes D et al (1986) When should levodopa be started? Lancet 328(8513):985–986
doi: 10.1016/S0140-6736(86)90642-2
Rajput AH, Stern W, Laverty WH (1984) Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 34:991–996. https://doi.org/10.1212/WNL.34.8.991
doi: 10.1212/WNL.34.8.991
pubmed: 6540397
Riederer P (1988) Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson’s disease. J Neural Transm Suppl 27:191–199. https://doi.org/10.1007/978-3-7091-8954-2_16
doi: 10.1007/978-3-7091-8954-2_16
pubmed: 3165434
Riesenberg R, Werth J, Zhang Y et al (2020) PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. https://doi.org/10.1177/1756286420911296
doi: 10.1177/1756286420911296
pubmed: 32201505
pmcid: 7066585
Rodríguez-Violante M, Ospina-García N, Dávila-Avila NM et al (2018) Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson’s disease. Arq Neuropsiquiatr 76:517–521. https://doi.org/10.1590/0004-282x20180074
doi: 10.1590/0004-282x20180074
pubmed: 30231124
Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6–9. https://doi.org/10.1056/NEJMP068265
doi: 10.1056/NEJMP068265
pubmed: 17202450
Schachter M, Blackstock J, Dick JPR et al (1979) Lisuride in Parkinson’s disease. Lancet 2:1129. https://doi.org/10.1016/S0140-6736(79)92523-6
doi: 10.1016/S0140-6736(79)92523-6
pubmed: 91855
Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38. https://doi.org/10.1056/NEJMOA062222
doi: 10.1056/NEJMOA062222
pubmed: 17202453
Schapira AHV, McDermott MP, Barone P et al (2013) Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747–755. https://doi.org/10.1016/S1474-4422(13)70117-0
doi: 10.1016/S1474-4422(13)70117-0
pubmed: 23726851
pmcid: 3714436
Scheller D, Ullmer C, Berkels R et al (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmied Arch Pharmacol 379:73–86. https://doi.org/10.1007/s00210-008-0341-4
doi: 10.1007/s00210-008-0341-4
Schuepbach WMM, Rau J, Knudsen K et al (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368:610–622. https://doi.org/10.1056/NEJMOA1205158
doi: 10.1056/NEJMOA1205158
pubmed: 23406026
Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 56:251–253. https://doi.org/10.1097/01.wnf.0000171195.68116.d0
doi: 10.1097/01.wnf.0000171195.68116.d0
pubmed: 14913646
Schwabe U (2008) Parkinsonmittel. Arzneiverordnungs-Report 2007:761–773. https://doi.org/10.1007/978-3-540-72548-0_41
doi: 10.1007/978-3-540-72548-0_41
Seeman P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189. https://doi.org/10.1002/syn.21805
doi: 10.1002/syn.21805
pubmed: 25645960
Seeman P, van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264–270. https://doi.org/10.1016/0165-6147(94)90323-9
doi: 10.1016/0165-6147(94)90323-9
pubmed: 7940991
Sheng Y, Zhou X, Yang S et al (2021) Modelling item scores of unified Parkinson’s disease rating scale part III for greater trial efficiency. Br J Clin Pharmacol 87:3608–3618. https://doi.org/10.1111/bcp.14777
doi: 10.1111/bcp.14777
pubmed: 33580584
Shi L, Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42:437–467. https://doi.org/10.1146/annurev.pharmtox.42.091101.144224
doi: 10.1146/annurev.pharmtox.42.091101.144224
pubmed: 11807179
Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69. https://doi.org/10.1016/0165-6147(92)90025-2
doi: 10.1016/0165-6147(92)90025-2
pubmed: 1561715
Stibe CMH, Kempster PA, Lees AJ, Stern GM (1988) Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet 331:403–406. https://doi.org/10.1016/S0140-6736(88)91193-2
doi: 10.1016/S0140-6736(88)91193-2
Stocchi F, Rascol O, Kieburtz K et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27. https://doi.org/10.1002/ANA.22060
doi: 10.1002/ANA.22060
pubmed: 20582993
Stowe R, Ives N, Clarke CE et al (2011) Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Mov Disord 26:587–598. https://doi.org/10.1002/mds.23517
doi: 10.1002/mds.23517
pubmed: 21370258
Tinsley RB, Bye CR, Parish CL et al (2009) Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 66:472–484. https://doi.org/10.1002/ANA.21716
doi: 10.1002/ANA.21716
pubmed: 19847912
Vaillancourt DE, Schonfeld D, Kwak Y et al (2013) Dopamine overdose hypothesis: evidence and clinical implications. Mov Disord 28:1920–1929. https://doi.org/10.1002/mds.25687
doi: 10.1002/mds.25687
pubmed: 24123087
van Holstein M, Aarts E, van der Schaaf ME et al (2011) Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology 218:567–578. https://doi.org/10.1007/s00213-011-2340-2
doi: 10.1007/s00213-011-2340-2
pubmed: 21611724
pmcid: 3210362
Wang J, Liu ZL, Chen B (2001) Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Neurosci Lett 308:21–24. https://doi.org/10.1016/S0304-3940(01)01971-1
doi: 10.1016/S0304-3940(01)01971-1
pubmed: 11445276
Wang S, Wacker D, Levit A et al (2017) D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358:381–386. https://doi.org/10.1126/SCIENCE.AAN5468
doi: 10.1126/SCIENCE.AAN5468
pubmed: 29051383
pmcid: 5856174
Wang S, Che T, Levit A et al (2018a) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555:269–273. https://doi.org/10.1038/nature25758
doi: 10.1038/nature25758
pubmed: 29466326
pmcid: 5843546
Wang Y, Yu X, Zhang P et al (2018b) Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson’s disease. J Pharmacol Sci 138:31–37. https://doi.org/10.1016/j.jphs.2018.08.008
doi: 10.1016/j.jphs.2018.08.008
pubmed: 30241783
Watanabe AM, Chase TN, Cardon PV (1970) Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther 11:740–746. https://doi.org/10.1002/CPT1970115740
doi: 10.1002/CPT1970115740
pubmed: 5455636
Wei SZ, Yao XY, Wang CT et al (2021) Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease. Brain Res Bull 177:363–372. https://doi.org/10.1016/J.BRAINRESBULL.2021.10.015
doi: 10.1016/J.BRAINRESBULL.2021.10.015
pubmed: 34699917
Wilson SM, Wurst MG, Whatley MF, Daniels RN (2020) Classics in chemical neuroscience: pramipexole. ACS Chem Neurosci 11:2506–2512. https://doi.org/10.1021/ACSCHEMNEURO.0C00332/ASSET/IMAGES/LARGE/CN0C00332_0002.JPEG
doi: 10.1021/ACSCHEMNEURO.0C00332/ASSET/IMAGES/LARGE/CN0C00332_0002.JPEG
pubmed: 32786316
Yin J, Chen KYM, Clark MJ et al (2020) Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. Nature 584:125–129. https://doi.org/10.1038/S41586-020-2379-5
doi: 10.1038/S41586-020-2379-5
pubmed: 32528175
pmcid: 7415663
Yokochi M (2007) Mesolimbic and mesocortical pathways in Parkinson disease. Brain Nerve 59:943–951
pubmed: 17886476
Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46. https://doi.org/10.1056/NEJMOA054830
doi: 10.1056/NEJMOA054830
pubmed: 17202454
Zhang J, Xiong B, Zhen X, Zhang A (2009) Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev 29:272–294. https://doi.org/10.1002/med.20130
doi: 10.1002/med.20130
pubmed: 18642350
Zhang YH, Tang BS, Song CY et al (2013) The relationship between the phenotype of Parkinson’s disease and levodopa-induced dyskinesia. Neurosci Lett 556:109–112. https://doi.org/10.1016/J.NEULET.2013.10.018
doi: 10.1016/J.NEULET.2013.10.018
pubmed: 24135335
Zis P, Grünewald RA, Chaudhuri RK, Hadjivassiliou M (2017) Peripheral neuropathy in idiopathic Parkinson’s disease: a systematic review. J Neurol Sci 378:204–209. https://doi.org/10.1016/j.jns.2017.05.023
doi: 10.1016/j.jns.2017.05.023
pubmed: 28566165
Zou H, Aggarwal V, Stebbins GT et al (2022) Application of longitudinal item response theory models to modeling Parkinson’s disease progression. CPT Pharmacometrics Syst Pharmacol 11:1382–1392. https://doi.org/10.1002/psp4.12853
doi: 10.1002/psp4.12853
pubmed: 35895005
pmcid: 9574723